Outlook Therapeutics (OTLK) Receivables (2015 - 2026)

Outlook Therapeutics (OTLK) posted quarterly Receivables of $2.7 million for Q1 2026, up 2273.14% quarter-over-quarter from $114609.0 in Q4 2025.

Outlook Therapeutics (OTLK) Receivables (2015 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Receivables for 4 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $1.5 million, changed N/A from the prior year.
Receivables advanced to $2.7 million in Q1 2026 per OTLK's latest filing, from $114609.0 in the prior quarter.
Across five years, Receivables topped out at $2.7 million in Q1 2026 and bottomed at $114609.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Outlook Therapeutics	88.50 Mn	77.26 Mn	-8,265.00	1.64 Mn

Download Data